Biomedical IRAS


This theme focuses on investigating health and disease to develop improved diagnostics and technologies for enhanced quality of life. It aims to explore how artificial intelligence and autonomous systems may be developed and applied to patient data sets, laboratory-based data collection, large spectroscopic data and data from emerging technologies for efficient and robust analysis, interpretation and diagnosis. Thus, the scope is wide and encompasses a range of experimental and analytical approaches. This theme aligns with the development of the health innovation campus and the Health theme within the Data Science Institute. This alignment aims to strengthen connections and collaborations in these areas across all faculties at Lancaster University.

Theme Leads

Jemma Kerns

Dr Jemma Kerns FHEA

Senior Lecturer and Director of Research

Biomedical, Centre for Ageing Research, Experimental Medicine, Lancaster Intelligent, Robotic and Autonomous Systems Centre

Amy Gadoud

Dr Amy Gadoud

Clinical Senior Lecturer in Palliative Medicine

Biomedical, Clinical, International Observatory on End of Life Care


Joanne Knight

Professor Joanne Knight

Chair in Applied Data Science

CHICAS, DSI - Health, FHM Mental Health Theme

B006, B - Floor, Furness College
Hedley Emsley

Professor Hedley Emsley

Professor of Clinical Neuroscience

Biomedical, Clinical



  • £85,793: J Kerns; Academy of Medical Sciences, 18 months; May 2018-Oct 2019. ‘How does gene and protein expression, of collagen, affect the chemical and material properties of osteoarthritic bone?’
  • £90,134 (to Lancaster University; £158k total): 2016, 12 months; J Kerns; Innovate UK. ‘Combined Novel 3D Cell Culture and Biospectroscopy; personalising Osteoporosis therapeutics’. Collaboration with Revivocell.
  • £900, A Che; Material Science Institute (MSI) small grant scheme, 2019: Developing in vitro model of osteoarthritic osteoblast using MG63 cell line.
  • Canadian $99,721, J Knight, 2017-19; Canadian Institute of Health Research: Do men and women differ in how pharmacogenetics optimises smoking cessation therapy?
  • $150,000, J Knight, 2017-20; Alzheimer’s Association and Brain Canada: Neuroinflammatory susceptibility to vascular disease as a dementia driver.
  • £83,331.20, J Knight, 2016-2019; Wellcome Trust: Multiple lines of evidence will improve power to identify genes: multiple lines of evidence will improve power to identify genes involved in complex traits.
  • £77,264, A Gadoud, 2019-20; Sir John Fisher Foundation: The use of data science to improve end-of-life care